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Background. Autism is a spectrum of neurodevelopmental disorders with manifestation within 3 years after birth. Manifestations
of autism include behavior problems (hyperactivity, toys destruction, self-harm, and agression) and sleep and eating disorders.
Etiology of autism is poorly understood. Oxidative stress and antioxidants can participate in pathobiochemical mechanisms of
autism.Methods. Twenty-four children, aged 3–6 years, with autismaccording to theDSMIVcriteria andusingCARSwere included
in the study. Concentrations of CoQ
10−TOTAL, 𝛾- and 𝛼-tocopherol, 𝛽-carotene, and lipid peroxidation were determined in plasma
before and after three months of supportive therapy with ubiquinol at a daily dose 2×50mg. Data on behavior of the children were
collected from parents at the same time. Results. Ubiquinol supportive therapy improved symptoms in children with autism, as
communication with parents (in 12%), verbal communication (in 21%), playing games of children (in 42%), sleeping (in 34%), and
food rejection (in 17%), with CoQ
10−TOTAL plasma level above 2.5 𝜇mol/L. Conclusions. Beneficial effect of ubiquinol in children
with autism has been demonstrated for the first time. We assume that plasma concentration of CoQ
10−TOTAL and lipid peroxidation
could be used as relevant biomarkers of ubiquinol supportive therapy.
1. Introduction
Autism Spectrum Disorders (ASDs) are neurodevelopmen-
tal disorders with manifestation within three years after
birth,occurring in male and in female in ratio of 4 : 1. ASDs
manifestations of autism include behavior problems (hyper-
activity, toys destruction, self-harm, and aggression) and
sleep and eating disorders, which may result from an inter-
action between genetic, environmental, and immunological
factors [1].The evidence suggests that various factors may be
involved in the etiopathogenesis of autism, such as oxidative
stress, antioxidant defence systems, brain mitochondrial dys-
function, impaired immune responses, environmental toxins,
and genetic disorders [2–5]. However, etiology of autism is
poorly understood.
Potential mechanisms that may link oxidative stress to
neuronal dysfunction, clinical symptoms, and pathogenesis
of autism include membrane lipid abnormalities, decreased
cellular membrane fluidity, immune and inflammatory
response, increased excitotoxicity, abnormal iron and cop-
per metabolism [6], imbalance in homocysteine/methionine
metabolism, increased nitric oxide and xanthine oxidase, and
mitochondrial dysfunction and abnormal energymetabolism
[4, 6, 7]. Antioxidant defence systems in autism can be
activated [8] or decreased [9]. Total antioxidant status was
reduced in Asperger individuals (mild subtype of autism)
compared with healthy controls [10]. Levels of major antiox-
idant serum proteins, namely, transferrin (iron-binding
protein) and ceruloplasmin (copper-binding protein) are
decreased in children with autism. Decreased blood levels
of reduced glutathione, glutathione peroxidase (GSH-Px),
methionine and cysteine, and increased oxidized glutathione
were reported in autistic patients in comparison with healthy
subjects [11]. Activity of erythrocyte superoxide dismutase
(SOD), erythrocyte, and plasma GSH-Px in children with
autismwere significantly lower than in subjects with standard
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development.These results indicate that children with autism
have low level of blood antioxidant enzyme systems [9, 12].
Increased antioxidant enzymes activities (SOD and xantine
oxidase) may reflect a previous cellular oxidative stress or
serve as a compensatorymechanism.The increased activity of
erythrocyte SOD and decreased catalase activitymay result in






Brain mitochondria play an important role in generation
of free radicals and ATP production. A key component





), an essential factor for cell bioenergetics. As
an antioxidant it decreases oxidative stress. Our previous
study determined baseline levels of CoQ10-OX, CoQ9-OX in
various rat brain regions and proved the bioavailability of
the liposomal ubiquinol to selected brain regions after its
administration into right brain ventricle. Our data indicate
that administration of ubiquinol may create the basis for
modulation of neuronal activities in specific brain regions
[13]. Based on these results, we expected beneficial effects
of ubiquinol supportive therapy in children with autism—
behavior, physiological functions, antioxidant status, and
lipid peroxidation.
2. Materials and Methods
2.1. Children with Autism. Twenty four children (17 boys,
7 girls; with male to female ratio 2.4 : 1), aged 3–6 years,
were included in the study according to the criteria of DSM
IV (Diagnostic and Statistical Manual of Mental Diseases,
USA) and using CARS (Childhood Autism Rating Scale, a
test combining parent reports and direct observation by the
professional) [14]. All parents signed an informed consent
with including their children to this project. Children were
coming fromhome settings. A placebo group of childrenwith
autism was not included in the study for ethical reason.
2.2. Psychological Test. Before the beginning of the study,
all children with neurology disturbances were examined
by psychologists, or neurologists. Children with obesity,
diabetes, or epilepsy were not included in the study. Parents
provided data about behavior of their children before and
after three months of ubiquinol supplementation (Table 1).
The screening tool was designed by a psychologist specifically
for the purposes of the presented study.
2.3. Ubiquinol Treatment. Liquid liposomal ubiquinol (Li-
QH—liposomal liquid reduced Coenzyme Q
10
, produced by
Tishcon corp., Westbury, New York, USA) was diluted in
milk, tea, or juice.
Children were supplemented during the first week at a
daily dose of 50mg ubiquinol. Evidence indicates beneficial
effects of treatment with higher doses; therefore after the
first week the daily dose was then increased to 2 × 50mg
ubiquinol (morning and at lunch with meal). If the children
were hyperactive, time of application was changed: 50mg
ubiquinol morning and 50mg ubiquinol early in the evening
before sleeping instead of at lunch time. Discontinuation of
Table 1: Effect of ubiquinol on psychological functions and behavior
in children with autism.




Toys destruction 19 3
Playing with friend 42 4
Communication with parents 12 0
Verbal communication 21 0
Food rejection 17 0
Sleep disorders 34 8
treatment after two months was in children with asthma (1),
broken leg (1), increased activity (1), aggression (2), and sleep
disorder (1). Children with autism were treated with last dose
of ubiquinol 24 hours before blood collection.
2.4. Biochemical Study. Plasma samples for estimation of
TBARS, CoQ10-TOTAL, 𝛼-tocopherol, 𝛾-tocopherol, and 𝛽-
carotene were prepared from blood and collected into tubes
with heparin after centrifugation at 1.96 ×g for 15 minutes.
2.5. Determination of TBARS in Plasma. Thiobarbituric acid
reactive substances (TBARS) in plasma were determined
spectrophotometrically by the method in [15].
2.6. Determination of 𝐶𝑜𝑄10-TOTAL, 𝛾-Tocopherol, 𝛼-
Tocopherol, and 𝛽-Carotene Concentrations. Antioxidants
(CoQ10-TOTAL, 𝛾-tocopherol, 𝛼-tocopherol, and 𝛽-caro-
tene) concentrations in the plasma were determined
simultaneously by isocratic high-performance liquid
chromatography (LKB, Sweden) according to [16, 17].
Oxidation of ubiquinol was performed before analysis
[18]. Plasma samples (500 𝜇L) were extracted by mixture
hexane/ethanol (5/2, v/v; Merck). Organic layer was
evaporated under nitrogen, and the residue dissolved in
99.9% ethanol and injected on the 7 𝜇m column SGX C18
(Tessek, Czech Republic). Elution was performed with
methanol/acetonitril/ethanol (6/2/2; v/v/v; Merck) and
flow rate 0.85mL/min. Concentrations of CoQ
10-OX were
detected spectrophotometrically at 275 nm, 𝛾-tocopherol
and 𝛼-tocopherol at 295 nm, and 𝛽-carotene at 450 nm,
using external standards (Sigma; Germany). Data were
collected and processed using CSW32 chromatographic
station (DataApex Ltd; Czech Republic).
Concentration of antioxidants (CoQ10-Total, 𝛾-tocopherol,
𝛼-tocopherol, and 𝛽-carotene) and lipid peroxidation were
determined in plasma before and after three months of
supportive therapy with ubiquinol.
2.7. Statistics. Statistical analysis of the data was made using
paired Student’s 𝑡-test. Differences between baseline values
and after three months of treatment were considered statis-
tically significant if corrected 𝑃 < 0.05.
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3. Results
Mean plasma TBARS and antioxidants (𝛼-tocopherol and 𝛽-
carotene) concentrations in children with autism were in ref-
erence range both at the baseline and also after three months
of ubiquinol treatment in comparison. Baseline 𝛾-tocopherol
concentrations were slightly below reference range and
increased after treatment. Mean baseline concentration of
CoQ10-TOTAL was in reference values. After three months of
ubiquinol treatment concentrations of CoQ10-TOTAL were in
the range of 1.633–5.496 𝜇mol/L. Significant improvement in
autistic symptomology was observed after three months of
ubiquinol supplementary therapy in children prevailingly at
over 2.5 𝜇mol/L CoQ10-TOTAL plasma concentration (Table 2).
Based on parents reports during the supportive therapy
improved communication with parents was observed in
12% of children, playing games with friends in 42%, verbal
communication in 21%, and sleeping in 34%, and food
rejection decreased in 17%, aggressiveness decreased in 13%,
and self-harm decreased in 14% of the subjects (Table 1).
In rare cases, especially in the first days of ubiquinol sup-
plementation, opposite effects, such as increased destructive
manifestations of anger, hyperactivity, and sleep disorders
were observed. These cases were managed by modifying the
time of ubiquinol treatment (50mg ubiquinol morning and
50mg ubiquinol early in the evening before sleeping).
4. Discussion
Children with autism are more vulnerable to oxidative stress;
lipid peroxidation markers are elevated [9, 19]. Frustaci
et al. reviewed data on TBARS (the end product of lipid
peroxidation in the body) in patients with autism. Its plasma
concentration in autism is controversial, from increasing
over control values or decreasing in comparison with control
values [11]. Our previous study showed differences in baseline
values of TBARS, depending on age. In 44 children (34 boys
and 10 girls), aged 3–10 years, plasma level of TBARS was in
reference values (4.262 ± 0.085 𝜇mol/L), while in 12 children
(9 boys and 3 girls), aged 11–18 years, TBARS levels were
significantly higher (4.624 ± 0.177 𝜇mol/L, 𝑃 < 0.05) in
comparisonwith reference values. Ratio ofmale to femalewas
3 : 1.The presented study shows plasmaTBARS concentration
in reference values of children with autism aged 3–6 years
(Table 2). Several factors could contribute to the TBARS
plasma level in patients with autism, as age, metabolic
changes, and mitochondrial disturbances of brain and skele-
tal muscle. In the study obese children with autism, children
with diabetes, or epilepsy were not included. Baseline values
of antioxidants and TBARS were compared with reference
values. Control group and placebo group of children with
autism were not included in the study for ethical reason.
Additional studies with estimation of oxidative stress param-
eters in patients with autism are warranted.
Antioxidant defence systems and mitochondrial
dysfunction are included in pathobiochemical mechanism
of autism [4, 10]. Zoroglu et al. [8] documented increased
antioxidant enzymatic activities; other authors published low
level of blood antioxidant enzyme system in autistic children.
Krajcovicova-Kudlackova et al. [20] published insufficient
plasma concentrations of vitamins E and A and lycopene
in children with autism. In our study baseline values of
plasma antioxidants in children with autism as 𝛼-tocopherol,
𝛽-carotene, and CoQ10-TOTAL were in reference values
(Table 2).
If abnormalities of a dynamic balance between antiox-
idants and reactive oxygen radicals production are present
in brain, free radicals accumulation could damage brain
tissue [9, 12]. In children with autism (aged 4–10 years)
significantly lower levels of mitochondrial respiratory chain
proteins were found, as in complex III and V in cerebellum,
complex I in frontal cortex, and complexes II, III, and V in
the temporal cortex. Chauhan et al. [21] observed that deficits
in respiratory chain complexes in children with autism may
readjust to normal levels by adulthood. Mild mitochondrial
dysfunction manifested as carnitine deficiency accompanied
by elevation in lactate, alanine, and ammonia levels was
observed in autism [22]. Mitochondrial dysfunction with
increased membrane degradation, impairment of electron
transport chain activity, and decreased synthesis of ATP was
observed in the brain [6] and in muscle biopsy in children
with autism [23]. Classical mitochondrial diseases occur in
individuals with autism and are usually caused by genetic
anomalies of mitochondrial respiratory pathways [24]. In
lymphocytic mitochondria decreased activity of complex I,
higher mitochondrial rate of hydrogen peroxide production
mtDNAoverreplication, andmtDNAdeletions were found in
children with autism [3].
Elevated lactate, pyruvate, lactate/pyruvate ratio, ala-
nine, creatine kinase, ammonia, aspartate aminotransferase,
alanine aminotransferase activities, and low total carnitine
belong to the abnormal biomarkers of mitochondrial dys-
function in autism [1]. Early assessment of antioxidants status
would have better prognosis as it may decrease the oxidative
stress before inducing irreversible brain damage [19].
Nutrition supplementation is used in autism, such as
vitamin C, carnosine, zinc, reduced glutathione, fish oil
(rich in EPA), melatonin, and vitamin B6 in combination
with Mg [6]. Treatment also includes acetylcholin esterase
inhibitors, music and movement therapy [25], carnitine,
hyperbaric oxygen treatment [2], immunomodulation and
anti-inflammatory treatment, oxytocin, and vision therapy,
multivitamin/mineral complex, PUFA, elimination diets,
acupuncture, auditory integration training, andmassage [26].
In review [1] authors proposed possible antioxidant treatment
with carnitine, CoQ
10
, and high doses of B-vitamins. In our
study, the best improvement in behavioral and psychological
functions was observed after three months of ubiquinol
supportive therapy in children with autism at over 2.5 𝜇mol/L
CoQ10-TOTAL plasma concentration, which is used as curative
value [27].
Mitochondrial CoenzymeQ functions include regulation
of electron transport in the respiratory chain, receiving
electrons from complex I, complex II, and passing them
to complex III, and transfer of protons from fatty acids to
matrix. As an alternative Coenzyme Q function is possible in
regulation of permeability transition pore opening and nutri-
tion uptake through the Voltage Dependent Anion Channel
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Table 2: Effect of ubiquinol on TBARS and antioxidants in plasma of children with autism (in 𝜇mol/L).
Reference values Baseline values Ubiquinol (3 months)
TBARS <4.50 4.380 ± 0.153 4.200 ± 0.241
𝛾-Tocopherol 2.00–7.00 1.625 ± 0.160 1.927 ± 0.304
𝛼-Tocopherol 15–40 17.98 ± 0.920 19.14 ± 0.872
𝛽-Carotene 0.30–3.00 0.983 ± 0.164 0.804 ± 0.129
CoQ10-TOTAL 0.40–1.00 0.512 ± 0.164 3.016± 0.307∗
𝜇mol/L: micromol/liter; TBARS: thiobarbituric acids reactive substances; 𝛾-tocopherol: gamma-tocopherol; 𝛼-tocopherol: alpha-tocopherol; CoQ10-TOTAL










































Figure 1: Proposed novel Coenzyme Q binding site in Voltage Dependent Anion Channel of outer mitochondrial membrane.
CoQ—Coenzyme Q; VDAC—Voltage Dependent Anion Channel; ATP—adenosine triphosphate; ADP—adenosine diphosphate; Pi—
inorganic phosphate; I, II, III, IV, and V—respiratory chain complexes; H+—proton; e−—electron; Q-cycle—Coenzyme Q cycle; cyt c—














(VDAC) of outer mitochondrial membrane (Figure 1). We
assume that ubiquinol supportive therapy may improve
brain mitochondrial function and ATP production and affect
brain oxidative stress. The mechanism by which ubiquinol
decreases symptoms in children with autism is not fully
known.
5. Summary
Beneficial effect of ubiquinol in children with autism has
been demonstrated for the first time. We assume that plasma
concentration of CoQ10-TOTAL and lipid peroxidation could
be used as important biomarkers of ubiquinol supportive
therapy. Additional study with a larger number of patients is
warranted to confirm these promising findings.
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